首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1532535

生物製藥發酵系統市場 - 產品類型（上游 [生物反應器、生物過程分析儀]、下游 [色譜、過濾]）、應用（重組蛋白、抗生素、益生菌）、最終用戶 - 全球預測（2024 - 2032）

Biopharmaceutical Fermentation Systems Market - Product Type (Upstream [Bioreactor, Bioprocess Analyzer], Downstream [Chromatography, Filtration]), Application (Recombinant Proteins, Antibiotics, Probiotics), End User - Global Forecast (2024 - 2032)

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 123 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在生物技術產業擴張的推動下，2024年至2032年全球生物製藥發酵系統市場的複合年成長率將超過6%。隨著生技公司不斷開發新的生物製劑和生物相似藥，對高品質發酵系統的需求日益增加。在此背景下，2024 年 5 月，GE HealthCare 在格拉斯哥舉行的 ESTRO 2024 上推出了 Revolution RT。這種人工智慧增強型 CT 解決方案提高了成像準確性並簡化了工作流程，從而增強了個人化腫瘤護理。該公司推出了更新的 iRT 平台和 MIM 軟體產品組合，以解決複雜的癌症診斷和治療延遲問題。

生物製藥發酵系統對於生產複雜的生物藥物和實現可擴展、高效的製造流程至關重要。生物技術創新的激增和研發投資的增加擴大了對先進發酵技術的需求。這些因素得到了對個人化醫療和新穎治療方法的日益關注的支持，從而有利於市場前景。

整個生物製藥發酵系統市場根據產品類型、最終用戶、應用和地區進行分類。

在對後製處理的關注的推動下，下游產品領域到 2032 年將實現顯著的複合年成長率。高效的下游加工對於生物製藥產品的純化和配製、確保高品質至關重要。隨著生物製藥公司強調最佳化這些工藝，對先進發酵系統的需求不斷成長。此外，下游產品要求的複雜性需要複雜的技術來滿足多樣化和具有挑戰性的加工需求。生物製藥研究的不斷進步和藥物開發活動的不斷增加進一步推動了產品的採用。

由於重視開發有效的抗生素，到 2032 年，抗生素領域將在生物製藥發酵系統市場中佔據大量佔有率。隨著抗生素抗藥性的增加，迫切需要先進的發酵技術來生產具有增強功效的新型抗生素。生產需要精確且可擴展的發酵工藝，以確保抗生素品質和產量的一致性。此外，滿足嚴格的監管標準和加快新抗生素上市時間的需求也增加了對複雜發酵系統的需求。

由於對醫療保健創新和生物技術的高度重視，歐洲生物製藥發酵系統市場在 2024 年至 2032 年期間將錄得可觀的複合年成長率。歐洲是生物製藥研究的領導者，擁有許多專注於先進療法和個人化醫療的公司。這項承諾推動了對複雜發酵系統的需求，以支持高品質的藥物生產。嚴格的產品安全監管標準、生物技術投資的增加以及對新療法不斷成長的需求加速了該地區的市場成長。

產業生態系統分析
產業影響力
- 成長動力
  - 生物製藥需求不斷成長
  - 不斷增加開發新生物製藥和生物相似藥的投資
  - 增加生物製藥產品的法規核准
  - 擴大採用一次性發酵罐
- 產業陷阱與挑戰
  - 高初始資本投資要求
  - 與可萃取物和可浸出物相關的問題
成長潛力分析
監管環境
未來市場趨勢
差距分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2032

主要趨勢
上游產品
- 生物反應器/發酵罐
- 生物過程分析儀
- 過程監控系統
- 其他上游產品
下游產品
- 過濾與分離
- 色譜法
- 耗材及配件
- 其他下游產品

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
重組蛋白
抗生素
益生菌
其他應用

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

主要趨勢
生物製藥公司
合約研究組織
學術研究機構
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Agilent Technologies, Inc.
Becton, Dickinson and Company
Bioengineering AG
Cellexus Limited
Danaher Corporation
Eppendorf AG
F. Hoffmann-La Roche Ltd.
GE HealthCare Technologies, Inc.
Getinge Group
Lonza Group AG
Merck KGaA
Nova Biomedicals
Sartorius Stedim Biotech
Thermo Fisher Scientific Inc.
ZETA

簡介目錄

Product Code: 9589

Global Biopharmaceutical Fermentation Systems Market will witness over 6% CAGR from 2024 to 2032, driven by the expansion of the biotechnology sector. As biotech companies continue developing new biologics and biosimilars, the need for high-quality fermentation systems intensifies. Against this backdrop, in May 2024, GE HealthCare launched Revolution RT at ESTRO 2024 in Glasgow. This AI-enhanced CT solution improves imaging accuracy and simplifies workflows, enhancing personalized oncology care. The company unveiled the updated iRT platform and MIM Software portfolio to address complex cancer diagnostics and treatment delays.

Biopharmaceutical fermentation systems are essential for producing complex biological drugs and achieving scalable, efficient manufacturing processes. The surge in biotech innovation and increased investment in R&D amplifies the demand for advanced fermentation technologies. These factors are supported by the growing focus on personalized medicine and novel therapeutic approaches, in turn favoring the market outlook.

The overall biopharmaceutical fermentation systems market is classified based on product type, end-user, application, and region.

The downstream products segment will register a notable CAGR through 2032, driven by a focus on post-production processing. Efficient downstream processing is crucial for purifying and formulating biopharmaceutical products, ensuring high quality. As biopharmaceutical companies emphasize optimizing these processes, the need for advanced fermentation systems grows. Additionally, the complexity of downstream product requirements necessitates sophisticated technologies that can handle diverse and challenging processing needs. The ongoing advancements in biopharmaceutical research and the increasing volume of drug development activities are further fueling the product adoption.

The antibiotics segment will garner a substantial biopharmaceutical fermentation systems market share by 2032, owing to the emphasis on developing effective antibiotics. As antibiotic resistance grows, there is a pressing demand for advanced fermentation technologies to produce novel antibiotics with enhanced efficacy. The manufacturing requires precise and scalable fermentation processes to ensure the consistent quality & yield of antibiotics. Additionally, the need to meet stringent regulatory standards and accelerate time-to-market for new antibiotics catapults the demand for sophisticated fermentation systems.

Europe biopharmaceutical fermentation systems market will record a considerable CAGR during 2024-2032, because of the strong emphasis on healthcare innovation and biotechnology. Europe is a leader in biopharmaceutical research, with numerous companies focusing on advanced therapies and personalized medicine. This commitment drives the need for sophisticated fermentation systems to support high-quality drug production. Strict regulatory standards for product safety, the increasing investment in biotechnology, and the growing demand for new treatments accelerate the market growth in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing demand for biopharmaceuticals
  - 3.2.1.2 Growing investments for developing new biopharmaceuticals and biosimilars
  - 3.2.1.3 Increasing regulatory approvals for biopharmaceutical products
  - 3.2.1.4 Growing adoption of single use fermenters
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Requirements for high initial capital investments
  - 3.2.2.2 Issues related to extractables and leachables
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Gap analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Upstream products
- 5.2.1 Bioreactors/fermenters
- 5.2.2 Bioprocess analyzers
- 5.2.3 Process monitoring systems
- 5.2.4 Other upstream products
5.3 Downstream products
- 5.3.1 Filtration & separation
- 5.3.2 Chromatography
- 5.3.3 Consumables & accessories
- 5.3.4 Other downstream products

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Recombinant proteins
6.3 Antibiotics
6.4 Probiotics
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Biopharmaceutical companies
7.3 Contract research organizations
7.4 Academic research institutes
7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa